Skip to main content
Erschienen in: Hepatology International 6/2022

04.08.2022 | Original Article

Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle

verfasst von: Jules Sotty, Pierre Bablon, Bouchra Lekbaby, Jérémy Augustin, Morgane Girier-Dufournier, Lucas Langlois, Céline Dorival, Fabrice Carrat, Stanislas Pol, Hélène Fontaine, Nazim Sarica, Christine Neuveut, Chantal Housset, Dina Kremdsorf, Aurélie Schnuriger, Patrick Soussan

Erschienen in: Hepatology International | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Besides the prototypical hepatitis B virus (HBV) infectious particle, which contains a full-length double-stranded DNA (flDNA), additional circulating virus-like particles, which carry pregenomic RNA (pgRNA), spliced1RNA (sp1RNA) or spliced-derived DNA (defDNA) forms have been described. We aimed to determine the level of these four circulating forms in patients and to evaluate their impact on viral lifecycle.

Methods

Chronic HBV untreated patients (n = 162), included in the HEPATHER cohort, were investigated. Pangenomic qPCRs were set up to quantify the four circulating forms of HBV nucleic acids (HBVnaf). In vitro infection assays were performed to address the impact of HBVnaf.

Results

Hierarchical clustering individualized two clusters of HBVnaf diversity among patients: (1) cluster 1 (C1) showing a predominance of flDNA; (2) cluster 2 (C2) showing various proportions of the different forms. HBeAg-positive chronic hepatitis phase and higher viral load (7.0 ± 6.4 vs 6.6 ± 6.2 Log10 copies/ml; p < 0.001) characterized C2 compared to C1 patients. Among the different HBVnaf, pgRNA was more prevalent in C1 patients with high vs low HBV viral load (22.1% ± 2.5% vs 4.1% ± 1.8% of HBVnaf, p < 0.0001) but remained highly prevalent in C2 patients, whatever the level of replication. C2 patients samples used in infection assays showed that: (1) HBVnaf secretion was independent of the viral strain; (2) the viral cycle efficiency differed according to the proportion of HBVnaf in the inoculum, independently of cccDNA formation. Inoculum enrichment before infection suggests that pgRNA-containing particles drive this impact on viral replication.

Conclusion

Besides the critical role of HBV replication in circulating HBVnaf diversity, our data highlight an impact of this diversity on the dynamics of viral cycle.

Clinical trial registration

Patients were included from a prospective multicenter French national cohort (ANRS CO22 HEPATHER, NCT01953458).

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370–398 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370–398
2.
Zurück zum Zitat Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015;479–480:672–686PubMedCrossRef Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015;479–480:672–686PubMedCrossRef
3.
Zurück zum Zitat Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol 2018;92:e00798-18CrossRef Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol 2018;92:e00798-18CrossRef
4.
Zurück zum Zitat Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 2017;9(3):56CrossRef Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 2017;9(3):56CrossRef
5.
Zurück zum Zitat Kouwaki T, Fukushima Y, Daito T, et al. Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection. Front Immunol 2016;7:335PubMedPubMedCentralCrossRef Kouwaki T, Fukushima Y, Daito T, et al. Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection. Front Immunol 2016;7:335PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Pol JG, Lekbaby B, Redelsperger F, et al. Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-alpha-stimulated signaling pathways and limits the extent of liver inflammation. FASEB J 2015;29:1879–1889PubMedCrossRef Pol JG, Lekbaby B, Redelsperger F, et al. Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-alpha-stimulated signaling pathways and limits the extent of liver inflammation. FASEB J 2015;29:1879–1889PubMedCrossRef
7.
Zurück zum Zitat Soussan P, Garreau F, Zylberberg H, et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest 2000;105:55–60PubMedPubMedCentralCrossRef Soussan P, Garreau F, Zylberberg H, et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest 2000;105:55–60PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Soussan P, Pol J, Garreau F, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis 2008;198:218–225PubMedCrossRef Soussan P, Pol J, Garreau F, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis 2008;198:218–225PubMedCrossRef
9.
Zurück zum Zitat Kremsdorf D, Lekbaby B, Bablon P, et al. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021, 70:2373–2382 Kremsdorf D, Lekbaby B, Bablon P, et al. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021, 70:2373–2382
10.
Zurück zum Zitat Bayliss J, Lim L, Thompson AJ, et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol 2013;59:1022–1028PubMedCrossRef Bayliss J, Lim L, Thompson AJ, et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol 2013;59:1022–1028PubMedCrossRef
11.
Zurück zum Zitat Duriez M, Mandouri Y, Lekbaby B, et al. Alternative splicing of hepatitis B virus: a novel virus/host interaction altering liver immunity. J Hepatol 2017;67:687–699PubMedPubMedCentralCrossRef Duriez M, Mandouri Y, Lekbaby B, et al. Alternative splicing of hepatitis B virus: a novel virus/host interaction altering liver immunity. J Hepatol 2017;67:687–699PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Lim CS, Sozzi V, Littlejohn M, et al. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 2021;7 Lim CS, Sozzi V, Littlejohn M, et al. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 2021;7
13.
Zurück zum Zitat Redelsperger F, Lekbaby B, Mandouri Y, et al. Production of hepatitis B defective particles is dependent on liver status. Virology 2012;431:21–28PubMedCrossRef Redelsperger F, Lekbaby B, Mandouri Y, et al. Production of hepatitis B defective particles is dependent on liver status. Virology 2012;431:21–28PubMedCrossRef
14.
Zurück zum Zitat Soussan P, Tuveri R, Nalpas B, et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003;38:343–348PubMedCrossRef Soussan P, Tuveri R, Nalpas B, et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003;38:343–348PubMedCrossRef
15.
Zurück zum Zitat Lam AM, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother 2017;61:e0080-17CrossRef Lam AM, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother 2017;61:e0080-17CrossRef
16.
Zurück zum Zitat Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B. Clin Infect Dis 2021;72:202–211PubMedCrossRef Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B. Clin Infect Dis 2021;72:202–211PubMedCrossRef
17.
Zurück zum Zitat Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 2021;74:2395–2409PubMedCrossRef Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 2021;74:2395–2409PubMedCrossRef
18.
Zurück zum Zitat Goncalves A, Lemenuel-Diot A, Cosson V, et al. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383–392PubMedCrossRef Goncalves A, Lemenuel-Diot A, Cosson V, et al. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383–392PubMedCrossRef
19.
Zurück zum Zitat Jansen L, Kootstra NA, van Dort KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2016;213:224–232PubMedCrossRef Jansen L, Kootstra NA, van Dort KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2016;213:224–232PubMedCrossRef
20.
Zurück zum Zitat Kaewdech A, Tangkijvanich P, Sripongpun P, et al. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961–2971PubMedCrossRef Kaewdech A, Tangkijvanich P, Sripongpun P, et al. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961–2971PubMedCrossRef
21.
Zurück zum Zitat Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol 2019;19:53PubMedPubMedCentralCrossRef Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol 2019;19:53PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Liu Y, Xue J, Liao W, et al. Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy. J Clin Gastroenterol 2020;54:e73–e82PubMedPubMedCentralCrossRef Liu Y, Xue J, Liao W, et al. Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy. J Clin Gastroenterol 2020;54:e73–e82PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 2021;73:2167–2179PubMedCrossRef Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 2021;73:2167–2179PubMedCrossRef
24.
Zurück zum Zitat van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66–76PubMedCrossRef van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66–76PubMedCrossRef
25.
Zurück zum Zitat van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat 2020;27:610–619PubMedPubMedCentralCrossRef van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat 2020;27:610–619PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016;65:700–710PubMedCrossRef Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016;65:700–710PubMedCrossRef
27.
Zurück zum Zitat Xiang Y, Yang Y, Chen P, et al. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA. Medicine (Baltimore) 2021;100:e27433PubMedCrossRef Xiang Y, Yang Y, Chen P, et al. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA. Medicine (Baltimore) 2021;100:e27433PubMedCrossRef
28.
Zurück zum Zitat Xie Y, Li M, Ou X, et al. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856–867PubMedPubMedCentralCrossRef Xie Y, Li M, Ou X, et al. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856–867PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Yu XQ, Wang MJ, Yu DM, et al. Comparison of serum hepatitis B virus rna levels and quasispecies evolution patterns between entecavir and pegylated-interferon MONO-treatment in chronic hepatitis B patients. J Clin Microbiol 2020;58:e00075-20PubMedPubMedCentralCrossRef Yu XQ, Wang MJ, Yu DM, et al. Comparison of serum hepatitis B virus rna levels and quasispecies evolution patterns between entecavir and pegylated-interferon MONO-treatment in chronic hepatitis B patients. J Clin Microbiol 2020;58:e00075-20PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212–224PubMedCrossRef Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212–224PubMedCrossRef
31.
Zurück zum Zitat Ma G, Lou B, Lv F, et al. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: “Loss of HBsAg” maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264–269PubMedCrossRef Ma G, Lou B, Lv F, et al. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: “Loss of HBsAg” maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264–269PubMedCrossRef
32.
Zurück zum Zitat Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5’RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol 2020;73:40–51PubMedCrossRef Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5’RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol 2020;73:40–51PubMedCrossRef
33.
Zurück zum Zitat Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 2018;25:1038–1047PubMedCrossRef Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 2018;25:1038–1047PubMedCrossRef
34.
Zurück zum Zitat Wang X, Chi X, Wu R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4PubMedPubMedCentralCrossRef Wang X, Chi X, Wu R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Zhou Y, Peng Y, Yuan H, et al. Serum hepatitis B virus ribonucleic acid and its influencing factors in chronic hepatitis B. Adv Clin Exp Med 2021;30:361–367PubMedCrossRef Zhou Y, Peng Y, Yuan H, et al. Serum hepatitis B virus ribonucleic acid and its influencing factors in chronic hepatitis B. Adv Clin Exp Med 2021;30:361–367PubMedCrossRef
36.
Zurück zum Zitat Prakash K, Rydell GE, Larsson SB, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018;15:86PubMedPubMedCentralCrossRef Prakash K, Rydell GE, Larsson SB, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018;15:86PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Wang ML, Liao J, Ye F, et al. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol 2021;93:3688–3696PubMedCrossRef Wang ML, Liao J, Ye F, et al. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol 2021;93:3688–3696PubMedCrossRef
39.
Zurück zum Zitat Yu G, Chen R, Zheng S, et al. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerg Microbes Infect 2022;11:775–785PubMedPubMedCentralCrossRef Yu G, Chen R, Zheng S, et al. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerg Microbes Infect 2022;11:775–785PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Riviere L, Gerossier L, Ducroux A, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 2015;63:1093–1102PubMedCrossRef Riviere L, Gerossier L, Ducroux A, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 2015;63:1093–1102PubMedCrossRef
41.
Zurück zum Zitat Garcia-Garcia S, Cortese MF, Tabernero D, et al. Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: different quasispecies? World J Gastroenterol 2021;27:7144–7158PubMedPubMedCentralCrossRef Garcia-Garcia S, Cortese MF, Tabernero D, et al. Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: different quasispecies? World J Gastroenterol 2021;27:7144–7158PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol 2018;68:847–849PubMedCrossRef Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol 2018;68:847–849PubMedCrossRef
43.
Zurück zum Zitat Liu Y, Liu H, Hu Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination. Hepatology 2020;71:463–476PubMedCrossRef Liu Y, Liu H, Hu Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination. Hepatology 2020;71:463–476PubMedCrossRef
44.
Zurück zum Zitat Yao Y, Yang B, Chen Y, et al. RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element. J Virol 2019;93:e02161-18PubMedPubMedCentralCrossRef Yao Y, Yang B, Chen Y, et al. RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element. J Virol 2019;93:e02161-18PubMedPubMedCentralCrossRef
Metadaten
Titel
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle
verfasst von
Jules Sotty
Pierre Bablon
Bouchra Lekbaby
Jérémy Augustin
Morgane Girier-Dufournier
Lucas Langlois
Céline Dorival
Fabrice Carrat
Stanislas Pol
Hélène Fontaine
Nazim Sarica
Christine Neuveut
Chantal Housset
Dina Kremdsorf
Aurélie Schnuriger
Patrick Soussan
Publikationsdatum
04.08.2022
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 6/2022
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10389-6

Weitere Artikel der Ausgabe 6/2022

Hepatology International 6/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.